Biopharmaceutical company developing therapies for neurological diseases.
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to advancing innovative treatments for neurological diseases. Central to its mission is the development of transformative medicines designed to address critical unmet needs in patient care.
At the forefront of Longboard's pipeline is LP352, its lead product candidate currently undergoing Phase 1b/2a clinical trials. LP352 is specifically targeted at treating seizures associated with developmental and epileptic encephalopathies, reflecting the company's focus on neurological disorders with significant therapeutic gaps.
In addition to its advanced clinical candidate, Longboard Pharmaceuticals is actively progressing preclinical product candidates such as LP659 and LP143. These initiatives aim to expand treatment options across a spectrum of neurological conditions, demonstrating the company's comprehensive approach to therapeutic innovation.
Founded as Arena Neuroscience, Inc. and rebranded as Longboard Pharmaceuticals, Inc. in October 2020, the company is headquartered in La Jolla, California. Since its inception, Longboard has positioned itself as a leader in neurological therapeutics, leveraging cutting-edge research and development to drive meaningful advancements in patient outcomes.